Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.95 USD | +1.97% | -5.70% | -31.28% |
May. 24 | Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing | MT |
Apr. 20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Immunovant, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Immunovant, Inc.
Oppenheimer | |
Goldman Sachs | |
JPMorgan Chase | |
Wolfe Research | |
HC Wainwright | |
Deutsche Bank Securities | |
UBS | |
Truist Securities | |
Piper Sandler | |
Wells Fargo Securities | |
Citigroup | |
Guggenheim | |
Raymond James | |
Stifel Nicolaus | |
BofA Securities | |
Chardan Research | |
Cantor Fitzgerald | |
SVB Securities LLC | |
Chardan | |
Baird | |
SVB Leerink | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- IMVT Stock
- Consensus Immunovant, Inc.